Serrano, César http://orcid.org/0000-0003-1416-8739
Rothschild, Sara http://orcid.org/0000-0001-6602-3924
Villacampa, Guillermo
Heinrich, Michael C. http://orcid.org/0000-0003-3790-0478
George, Suzanne
Blay, Jean-Yves http://orcid.org/0000-0001-7190-120X
Sicklick, Jason K. http://orcid.org/0000-0003-4403-0271
Schwartz, Gary K.
Rastogi, Sameer
Jones, Robin L. http://orcid.org/0000-0003-4173-3844
Rutkowski, Piotr
Somaiah, Neeta http://orcid.org/0000-0002-0146-7732
Navarro, Víctor http://orcid.org/0000-0001-6925-4605
Evans, Denisse
Trent, Jonathan C.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (1 R21 CA263400-01)
Article History
First Online: 12 October 2023
Competing interests
: C.S. has received research funding (institution) from IDRX, Blueprint, Karyopharm, Pfizer, Deciphera and Bayer; consulting fees (advisory role) from Newbay, Cogent, Immunicum AB, Deciphera and Blueprint; payment for lectures from Roche, PharmaMar, Deciphera, Bayer and Blueprint; and travel grants from Gilead, PharmaMar, Pfizer and Bayer AG. M.C.H. reports consulting roles for Blueprint, Deciphera, C Stone Pharmaceuticals, Zai Labs, Cogent and Theseus Pharmaceuticals, and patents, royalties and other intellectual property regarding a patent on treatment of GIST-licensed to Novartis. G.V. has received speaker’s fees from MSD, GSK, Pfizer and Pierre Fabre, and has held an advisory role with AstraZeneca. S.G. has received funding (institution) from IDRX, Theseus, Blueprint, Deciphera, BioAtla, Springworks, Merck, Eisai and Daiichi Sankyo; consulting fees from Immunicum, Deciphera, Blueprint and Kayothera; equity in Abbott Labs; and other fees from WCG (Ayala-DSMB). J.-Y.B. receives research support (institution) from Deciphera, Eisai, Roche, Pharmamar, Bayer, GSK and MSD. J.K.S. receives consultant fees from Deciphera, Aadi and Grand Rounds; serves as a consultant for CureMatch; has received speaker’s fees from Deciphera, Hoffman-La Roche, Foundation Medicine, Merck, QED and Daiichi Sankyo; and owns stock in Personalis. R.L.J. reports consulting or advisory roles for Lilly, Immune Design, Merck Serono, Adaptimmune, Daiichi Sankyo, Eisai, Morphotek, TRACON Pharma, Immodulon Therapeutics, Deciphera, PharmaMar, Blueprint Medicines Corporation, Clinigen Group, Epizyme, Boehringer Ingelheim, Bayer, Karma Oncology and UpToDate; research funding from GlaxoSmithKline; and reimbursement of travel and accommodation expenses from PharmaMar. P.R. has received honoraria for lectures and Advisory Board meetings from MSD, BMS, Novartis, Pierre Fabre, Sanofi, Merck, Philogen and Astra Zeneca outside of the scope of this study. N.S. has received consulting fees (advisory role) from Deciphera, Bayer, Boehringer-Ingelheim, Epizyme and Aadi Biosciences. J.C.T. consulted for Blueprint, Deciphera, Cogent, Daiichi-Sankyo, Foghorn, Bayer and Adcendo. Life Raft Group, where S.R. and D.E. are employed, has received program-related grants from Blueprint, Cogent Biosciences, Daichii Sankyo, Deciphera, Genentech, IDRx, Novartis, Pfizer and Theseus. The remaining authors declare no conflicts of interest.